Introduction

Treatment of colorectal cancer as one of the most commonly diagnosed and a frequent cause of cancer-related deaths is of great challenges in health-related issues.

Areas covered

Immunotherapy is the fourth pillar of cancer treatment which provides more novel therapeutic options with expanding investigational potentials. One of the modalities in immunotherapy is the use of bispecific antibodies. Despite demonstrating many promising roles, it still needs more advanced studies to identify the actual pros and cons. In this review, the application of bispecific antibody in the treatment of colorectal cancer has been explained, based on preclinical and clinical studies. The literature search was conducted mainly through PubMed in June and September 2019.

Expert opinion

Bispecific antibody is in its early stages in colorectal cancer treatment, requiring modern technologies in manufacturing, better biomarkers and more specific target antigens, more studies on individual genetic variations, and conducting later phase clinical trials and systematic reviews to achieve better survival benefits.

中文翻译：

---

双特异性抗体在结直肠癌治疗中的研制及临床应用[J].

介绍

结直肠癌作为癌症相关死亡最常被诊断和最常见的原因之一，在与健康相关的问题上面临着巨大的挑战。

覆盖区域

免疫疗法是癌症治疗的第四大支柱，它提供了更多新颖的治疗选择，并具有不断扩大的研究潜力。免疫疗法的一种方式是使用双特异性抗体。尽管展示了许多有前途的作用，但它仍然需要更深入的研究来确定实际的利弊。在这篇综述中，基于临床前和临床研究，解释了双特异性抗体在治疗结直肠癌中的应用。文献检索主要通过 PubMed 于 2019 年 6 月和 9 月进行。

专家意见

双特异性抗体在结直肠癌治疗中处于早期阶段，需要现代制造技术、更好的生物标志物和更特异性的靶抗原、对个体遗传变异的更多研究，以及进行后期临床试验和系统评价以实现更好的生存获益。